A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

2023-506871-88-00 Protocol M22-947 Human pharmacology (Phase I) - Other Ongoing, recruitment ended

Start 7 Oct 2022 · Status Ongoing, recruitment ended · 4 EU/EEA countries · 21 sites · Protocol M22-947

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruitment ended
Participants planned 450
Countries 4
Sites 21

Relapsed/Refractory Multiple Myeloma

Key facts

Sponsor
AbbVie Deutschland GmbH & Co. KG
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
7 Oct 2022 → ongoing
Decision date (initial)
2024-01-10
Transition trial
Yes
Low-intervention
No
Rare-disease indication
Yes
Vulnerable population
Yes

External identifiers

EU CT number
2023-506871-88-00
EudraCT number
2021-005587-22
ClinicalTrials.gov
NCT05259839

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Relapsed/Refractory Multiple Myeloma

VersionLevelCodeTermSystem organ class
21.0 LLT 10028228 Multiple myeloma 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

AbbVie Deutschland GmbH & Co. KG

Sponsor organisation
AbbVie Deutschland GmbH & Co. KG
Address
Knollstrasse
City
Ludwigshafen Am Rhein
Postcode
67061
Country
Germany

Scientific contact point

Organisation
AbbVie Deutschland GmbH & Co. KG
Contact name
Global Clinical Trials Helpdesk

Public contact point

Organisation
AbbVie Deutschland GmbH & Co. KG
Contact name
Global Clinical Trials Helpdesk

Locations

4 EU/EEA countries · 21 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ongoing, recruitment ended 50 5
Italy Ongoing, recruitment ended 49 5
Poland Ongoing, recruitment ended 49 4
Spain Ongoing, recruitment ended 48 7
Rest of world
United States, Japan, Australia
254

Investigational sites

Germany

5 sites · Ongoing, recruitment ended
University Medical Center Hamburg-Eppendorf
N/A, Martinistrasse 52, Eppendorf, Hamburg
Universitaetsklinikum Regensburg
N/A, Franz-Josef-Straus-Allee 11, Gras-Oberisling, Ratisbon
Universitaetsklinikum Wuerzburg AöR
N/A, Oberduerrbacher Strasse 6, Grombuehl, Wuerzburg
Universitaetsklinikum Tuebingen AöR
N/A, Otfried-Mueller-Strasse 10, Nordstadt, Tuebingen
Universitaetsklinikum Essen AöR
N/A, Hufelandstrasse 55, Holsterhausen, Essen

Italy

5 sites · Ongoing, recruitment ended
Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.
Haematology, Via Piero Maroncelli 40, 47014, Meldola
Ospedale San Raffaele S.r.l.
Haematology, Via Olgettina 60, 20132, Milan
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
Haematology, Via Francesco Sforza 28, 20122, Milan
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Haematology, Largo Francesco Vito 1, 00168, Rome
Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico
Haematology, Via Pietro Albertoni 15, 40138, Bologna

Poland

4 sites · Ongoing, recruitment ended
Uniwersytecki Szpital Kliniczny Im. Jana Mikulicza-Radeckiego We Wroclawiu
Department of Hematology, Cell Therapies and Internal Diseases, Ul. Wybrzeze Ludwika Pasteura 4, 50-367, Wroclaw
Uniwersytecki Szpital Kliniczny Nr 1 W Lublinie
Department of Hematooncology and Bone Marrow Transplantation, Ul. Stanislawa Staszica 11, 20-081, Lublin
Szpital Wojewodzki W Opolu Sp. z o.o.
Department of Hematology, Hematological Oncology and Internal Medicine, Ul. Katowicka 64, 45-061, Opole
Uniwersyteckie Centrum Kliniczne
Department of Hematology and Transplantology, Ul. Mariana Smoluchowskiego 17, 80-214, Gdansk

Spain

7 sites · Ongoing, recruitment ended
Hospital Universitari Vall D Hebron
N/A, Edificio Materno-Infantil, Passeig De La Vall D'hebron 119-129, Barcelona
University Hospital Virgen Del Rocio S.L.
N/A, Avenida De Manuel Siurot S/n, 41013, Sevilla
Clinica Universidad De Navarra
N/A, Calle Marquesado De Santa Marta 1, 28027, Madrid
Clinica Universidad De Navarra
N/A, Avenue Pio XII 36, 31008, Pamplona
Institut Catala D'oncologia
N/A, Avinguda De La Gran Via De L'hospitalet 199-203, 08908, L'hospitalet De Llobregat
Hospital Universitario 12 De Octubre
N/A, Bloque D, Avenida De Cordoba Sn, Madrid
Hospital Clinic De Barcelona
N/A, Calle Villarroel 170, 08036, Barcelona

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2022-11-02 2022-12-15 2025-12-01
Italy 2022-12-14 2023-04-26 2025-12-01
Poland 2022-12-13 2023-01-10 2025-12-01
Spain 2022-10-07 2022-10-26 2025-07-15

Application history

7 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-11-20 Germany Acceptable
2024-01-10
2024-01-10
2 SUBSTANTIAL MODIFICATION SM-1 2024-04-02 Germany Acceptable
2024-06-03
2024-06-05
3 SUBSTANTIAL MODIFICATION SM-2 2024-08-20 Germany Acceptable
2024-11-25
2024-11-27
4 SUBSTANTIAL MODIFICATION SM-3 2025-01-13 Germany Acceptable
2025-04-07
2025-04-08
5 SUBSTANTIAL MODIFICATION SM-4 2025-04-16 Germany Acceptable 2025-06-02
6 SUBSTANTIAL MODIFICATION SM-5 2025-08-28 Germany Acceptable
2025-12-08
2025-12-10
7 SUBSTANTIAL MODIFICATION SM-6 2025-12-23 Germany Acceptable
2026-02-23
2026-02-24